The company and all members of the board guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or major omissions.
Special Reminder: The company's stock has been suspended from listing since March 15, 2019, for a period of six months. After the suspension, the Shenzhen Stock Exchange will decide whether to terminate the listing of the company's stock. If the listing is terminated, the stock trading will enter a delisting arrangement for thirty trading days.
Changsheng Biotechnology Co., Ltd. (hereinafter referred to as "the Company") and its wholly-owned subsidiary Changchun Changsheng Biotechnology Co., Ltd. (hereinafter referred to as "Changchun Changsheng") have been administratively punished by the National Medical Products Administration and the Jilin Provincial Food and Drug Administration for illegal production and sale of freeze-dried human rabies vaccine (Vero cells) (for specific details, please refer to the Company's announcements on October 16, 2018, in the Securities Times, Securities Daily, Shanghai Securities Journal, and the Giant Tide Information Network (www.cninfo.com.cn) regarding the administrative penalty decisions).